Abstract
1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have